Anteris Technologies Global Corp. (NASDAQ:AVR) Stock Has Average Price Target of $14.00 According to Brokerages

Shares of Anteris Technologies Global Corp. (NASDAQ:AVR) have received an average recommendation of “Hold” from the five research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $14.00.

AVR has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Wednesday, August 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $15.00 target price on shares of Anteris Technologies Global in a research note on Wednesday, October 14th. Finally, Barclays upgraded shares of Anteris Technologies Global to a “hold” rating in a report on Wednesday, October 7th.

Anteris Technologies Global Stock Down 0.8%

Shares of AVR stock opened at $5.89 on Friday. The stock has a 50-day moving average price of $7.13 and a 200 day moving average price of $7.39. The firm has a market cap of $574.04 million, a price-to-earnings ratio of -3.02 and a beta of 2.02. Anteris Technologies Global has a 12 month low of $3.30 and a 12 month high of $11.06.

Anteris Technologies Global (NASDAQ:AVR) last released its earnings results on Tuesday, November 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The company had revenue of $0.52 million for the quarter, compared to the consensus estimate of $2.75 million. Sell-side analysts predict that Anteris Technologies Global will post -1.21 earnings per share for the current fiscal year.

Insider Activity at Anteris Technologies Global

In other Anteris Technologies Global news, major shareholder L1 Capital Pty Ltd acquired 272,695 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The shares were acquired at an average price of $7.18 per share, with a total value of $1,957,950.10. Following the purchase, the insider owned 6,358,271 shares of the company’s stock, valued at $45,652,385.78. This represents a 4.48% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders have acquired 1,554,730 shares of company stock valued at $11,694,513. 4.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Anteris Technologies Global

A number of hedge funds have recently modified their holdings of AVR. Russell Investments Group Ltd. lifted its holdings in shares of Anteris Technologies Global by 18.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 30,472 shares of the company’s stock valued at $237,000 after purchasing an additional 4,736 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Anteris Technologies Global during the third quarter worth about $93,000. Forum Financial Management LP grew its holdings in shares of Anteris Technologies Global by 266.1% during the third quarter. Forum Financial Management LP now owns 40,008 shares of the company’s stock worth $311,000 after buying an additional 29,081 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Anteris Technologies Global by 26,789.3% during the third quarter. Farther Finance Advisors LLC now owns 15,058 shares of the company’s stock worth $117,000 after buying an additional 15,002 shares in the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in Anteris Technologies Global in the 2nd quarter valued at approximately $33,325,850.

About Anteris Technologies Global

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.